Trials
Search / Trial NCT06445244

α-ketoglutarate in Patients With Hypertension

Launched by JUN TAO · May 31, 2024

Trial Information

Current as of February 18, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a substance called alpha-ketoglutarate (αKG) on people with hypertension, which is high blood pressure. Hypertension can lead to serious heart and brain problems, so finding effective treatments is very important. αKG is a natural compound that helps with various processes in our bodies and has been shown to improve health as we age. Researchers want to see if taking αKG can help lower blood pressure and improve the health of blood vessels in patients with hypertension.

To participate in this study, you should be between 18 and 65 years old and have primary hypertension, meaning your blood pressure falls within specific ranges. It's important that you haven’t taken any medications or supplements that affect blood pressure in the last three months. Participants will be asked to follow the study's guidelines and will receive detailed information about the process, including potential risks and benefits. If you’re interested and meet the criteria, this trial could provide valuable insights into a new way to manage high blood pressure and improve vascular health.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1、 Primary hypertension (office blood pressure: systolic blood pressure 130~159 mmHg and/or diastolic blood pressure 80~99 mmHg, which meets the diagnostic criteria of hypertension class 1 of 2018AHA hypertension guidelines) and accompanied by vascular dysfunction (FMD\<5%); 2、 Age between 18 and 65 years old; 3, Not using any drugs and dietary supplements that affect blood pressure and vascular endothelial function in the last 3 months, mainly including antihypertensive, lipid-lowering, hypoglycemic drugs and natural plant extract antioxidants; 4、 Voluntarily sign the informed consent form after fully understanding the purpose and process of the study, disease characteristics, drug effects, methods of relevant examinations, and potential risks/benefits of the study.
  • Exclusion Criteria:
  • 1. Presence of secondary hypertension (those who have been diagnosed with secondary hypertension in the past and have not been definitively cured, and if secondary hypertension is suspected, a complete examination is required to exclude common secondary hypertension, including renal hypertension (renal parenchymal lesions, renal artery stenosis), primary aldosteronism, Cushing's syndrome, pheochromocytoma, aortic constriction, and severe obstructive sleep apnea);
  • 2. Acute myocardial infarction within the past 6 months;
  • 3. recent history of stroke (within 6 months); 4, Dilated heart disease, hypertrophic cardiomyopathy, rheumatic heart disease, congenital heart disease, severe heart valve disease (severe valve stenosis and or regurgitation);
  • 5. patients with a combination of serious physical illnesses, such as cancer; 6, Severe hepatic or renal dysfunction (ALT and or AST) ≥ 3 times the upper limit of normal, or dialysis end-stage renal disease or eGFR \< 30 ml/min/1.73 m2, or serum creatinine \> 2.5 mg/dL \[\> 221 μmol/L\]); 7. Symptomatic heart failure or reduced left ventricular ejection fraction (\<40%) within the past 6 months; 8. History of hypersensitivity to the study drug or to its components after administration; 9. Participating in other clinical studies; 10. Patients with mental illness who are unable to cooperate; 11, Pregnant, lactating or expectant mothers;

Trial Officials

Xia Wenhao, MD, PhD

Study Chair

Guangxi Hospital Division of The First Affiliated Hospital, Sun Yat-sen University

About Jun Tao

Jun Tao is a clinical trial sponsor dedicated to advancing medical research and improving patient outcomes through innovative therapeutic solutions. Committed to rigorous scientific methodologies and ethical practices, Jun Tao collaborates with leading researchers and healthcare institutions to design and conduct clinical trials across various therapeutic areas. With a focus on patient-centered approaches and a strong emphasis on safety and efficacy, Jun Tao aims to accelerate the development of groundbreaking treatments that address unmet medical needs and enhance the quality of care.

Locations

Guangxi, Nanning, China

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0